IL3 and neutropenia: IL-3 levels are stimulated by P-MAPA therapy, and this increase might be protective for patients during OC chemotherapy; administration of rhIL-3 to patients with platelet count < 75,000/mm3 is effective to fight thrombocytopenia and neutropenia after chemotherapy [36].